Neuroimmune Disease Comparison Matrix
Overview
flowchart TD
Neuroimmune_Disease_Comparison["Neuroimmune Disease Comparison Matrix"]
Neuroimmune_Disease_Comparison["page"]
Neuroimmune_Disease_Comparison -->|"related to"| Neuroimmune_Disease_Comparison
style Neuroimmune_Disease_Comparison fill:#81c784,stroke:#333,color:#000
Neuroimmune_Disease_Comparison["provides"]
Neuroimmune_Disease_Comparison -->|"related to"| Neuroimmune_Disease_Comparison
style Neuroimmune_Disease_Comparison fill:#81c784,stroke:#333,color:#000
Neuroimmune_Disease_Comparison["comprehensive"]
Neuroimmune_Disease_Comparison -->|"related to"| Neuroimmune_Disease_Comparison
style Neuroimmune_Disease_Comparison fill:#81c784,stroke:#333,color:#000
style Neuroimmune_Disease_Comparison fill:#4fc3f7,stroke:#333,color:#000
This page provides a comprehensive cross-disease comparison of key neuroimmune genes and proteins that regulate microglial function across major neurodegenerative diseases: Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). The five primary targets—[TREM2](/proteins/trem2), [CD33](/proteins/cd33), [PLD3](/proteins/pld3), [CSF1R](/proteins/csf1r), and [TYROBP](/proteins/tyrobp)—represent distinct but interconnected nodes of the neuroimmune signaling network.
...Neuroimmune Disease Comparison Matrix
Overview
Mermaid diagram (expand to render)
This page provides a comprehensive cross-disease comparison of key neuroimmune genes and proteins that regulate microglial function across major neurodegenerative diseases: Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). The five primary targets—[TREM2](/proteins/trem2), [CD33](/proteins/cd33), [PLD3](/proteins/pld3), [CSF1R](/proteins/csf1r), and [TYROBP](/proteins/tyrobp)—represent distinct but interconnected nodes of the neuroimmune signaling network.
Understanding the disease-specific roles and therapeutic targetability of these proteins is essential for developing cross-disease therapeutic strategies and identifying shared versus unique mechanisms of neurodegeneration["@decressac2024"].
Gene-by-Gene Cross-Disease Comparison
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
bfe67bb53c3c532ef4237fa3323691ae27404769
Key Mechanisms:
- Signals through [TYROBP](/mechanisms/tyrobp-dap12-microglia-pathway) (DAP12) adaptor protein
- Activates [SYK](/proteins/syk-protein), PI3K/AKT, and MAPK pathways
- Promotes phagocytosis of amyloid-beta, apoptotic cells, and lipid particles
- Critical for disease-associated microglia (DAM) formation
Cross-Disease Synthesis: TREM2 represents the most validated microglial target in AD, with clear genetic evidence (rare variants causing 3-4x risk increase). Emerging evidence suggests roles in PD (α-synuclein clearance) and ALS (microglial regulation of motor neuron environment), but these are less well-characterized.
CD33 (Siglec-3)
bfe67bb53c3c532ef4237fa3323691ae27404769
Key Mechanisms:
- Siglec family inhibitory receptor on microglia
- Binds sialic acid residues on glycoproteins
- Transduces inhibitory signals through ITIM motif
- Genetic variant rs3865444 affects splicing and is protective
Cross-Disease Synthesis: CD33's role is best characterized in AD, where it inhibits beneficial microglial phagocytosis. The protective variant reduces CD33 expression and is associated with reduced amyloid pathology. CD33's role in other diseases is less characterized, though single-cell studies suggest microglial upregulation across conditions.
PLD3 (Phospholipase D3)
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD |
|---------|-------------------|-------------------|-----|-----|
| Genetic Association | Strong (rare variants increase risk ~2x)[@cruchaga2014][@csg2017] | Limited | Limited | Limited |
| Expression | Neuronal and microglial | Neuronal | Neuronal | Neuronal |
| Function | Lysosomal function, autophagy | May affect α-synuclein processing | Not well characterized | Not well characterized |
| Therapeutic Status | Target validation ongoing | Not active | Not active | Not active |
| Mechanism | Endolysosomal function | Not well studied | Not well studied | Not well studied |
Key Mechanisms:
- Endolysosomal phospholipase D
- Critical for autophagy and lysosomal degradation
- PLD3 deficiency leads to lysosomal dysfunction and neurodegeneration in mouse models
- CRISPRi screens identify PLD3 as regulator of neurodegeneration pathways[@chen2020]
Cross-Disease Synthesis: PLD3 is primarily a neuronal endolysosomal protein with genetic evidence in AD. Unlike TREM2 and CD33 (microglial), PLD3 suggests that neuroimmune cross-talk involves neuronal vulnerability factors that affect microglial clearance.
CSF1R (Colony Stimulating Factor 1 Receptor)
bfe67bb53c3c532ef4237fa3323691ae27404769
Key Mechanisms:
- Receptor for [CSF1](/proteins/csf1-protein) and IL-34
- Critical for microglial development and maintenance
- CSF1R inhibition depletes microglia; withdrawal enables repopulation
- Novel "microglia depletion and repopulation" therapeutic strategy
Cross-Disease Synthesis: CSF1R is unique in having direct genetic causation in familial ALS (CSF1R mutations cause early-onset ALS/dementia). This positions CSF1R as a critical node linking microglial survival to motor neuron health. Therapeutic modulation (inhibition for depletion, activation for support) is being actively explored.
TYROBP (DAP12)
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD |
|---------|-------------------|-------------------|-----|-----|
| Genetic Association | Moderate (GWAS signals) | Limited | Limited | Limited |
| Expression | High in microglia | High in microglia | High in microglia | High in microglia |
| Function | TREM2 signaling adaptor | TREM2 signaling | TREM2/TYROBP signaling | TREM2 signaling |
| Therapeutic Status | Downstream of TREM2 | Downstream of TREM2 | Downstream of TREM2 | Downstream of TREM2 |
| Signaling | ITAM-mediated SYK activation | ITAM-mediated SYK activation | ITAM-mediated SYK activation | ITAM-mediated SYK activation |
Key Mechanisms:
- Adaptor protein (ITAM-bearing) for multiple receptors
- Primary signaling partner for [TREM2](/mechanisms/trem2-signaling)
- Enables downstream SYK, PLCγ, and PI3K/AKT activation
- TYROBP deficiency impairs microglial function
Cross-Disease Synthesis: TYROBP serves as the central signaling adaptor for TREM2 and other activating receptors. Its role is downstream of TREM2, meaning therapeutic targeting would affect all TYROBP-coupled receptors simultaneously.
Mechanism Comparison Table
| Mechanism | TREM2 | CD33 | PLD3 | CSF1R | TYROBP |
|-----------|-------|------|------|-------|--------|
| Primary Cell Type | Microglia | Microglia | Neurons | Microglia | Microglia |
| Signal Type | Activating | Inhibitory | Metabolic | Activating | Adaptor (ITAM) |
| Downstream Pathway | SYK, PI3K/AKT, MAPK | SHP-1/2 inhibition | Autophagy-lysosome | STAT3, PI3K/AKT | SYK, PLCγ |
| Genetic Validation (AD) | ★★★★★ | ★★★★☆ | ★★★★☆ | ★★☆☆☆ | ★★☆☆☆ |
| Genetic Validation (PD) | ★★☆☆☆ | ★☆☆☆☆ | ★☆☆☆☆ | ★★☆☆☆ | ★☆☆☆☆ |
| Genetic Validation (ALS) | ★★☆☆☆ | ★☆☆☆☆ | ★☆☆☆☆ | ★★★★☆ | ★★☆☆☆ |
| Genetic Validation (FTD) | ★☆☆☆☆ | ★☆☆☆☆ | ★☆☆☆☆ | ★★☆☆☆ | ★☆☆☆☆ |
| Therapeutic Targetability | High | High | Moderate | High | Moderate |
| Clinical Stage | Phase 2 | Preclinical | Discovery | Phase 1/2 | Discovery |
Therapeutic Targeting Matrix
| Target | Modulation | Approach | Disease Focus | Development Stage | Key Players |
|--------|-----------|----------|---------------|------------------|-------------|
| TREM2 | Agonism | Antibody (AL002, DHQ-Gly) | AD | Phase 2 | Alector/AbbVie |
| TREM2 | Agonism | Small molecule | AD | Preclinical | Various |
| CD33 | Antagonism | Antibody (JAX04) | AD | Preclinical | Janssen |
| CSF1R | Antagonism | Small molecule (PLX5622) | AD | Phase 1/2 | Cerevel |
| CSF1R | Antagonism | Antibody | AD/ALS | Preclinical | Various |
| PLD3 | Activation | Gene therapy/small molecule | AD | Discovery | - |
| TYROBP | Modulation | Indirect (via TREM2) | Multiple | Discovery | - |
Cross-Disease Synthesis
Shared Mechanisms
Microglial Phagocytosis Dysregulation: All five genes regulate microglial phagocytosis—TREM2 and TYROBP promote it, CD33 inhibits it, PLD3 enables lysosomal degradation, and CSF1R supports microglial survival for ongoing phagocytosis.
DAM/TREM2-Dependent Microglial Activation: The disease-associated microglia (DAM) program in AD requires [TREM2](/mechanisms/disease-associated-microglia). Evidence suggests similar programs operate in PD, ALS, and FTD, though less characterized.
Neuroimmune Checkpoint Dysfunction: The neuroimmune checkpoint framework—where activating signals (TREM2, CSF1R) and inhibitory signals (CD33) balance microglial function—is disrupted across all four diseases.Disease-Specific Mechanisms
| Disease | Unique Mechanism | Implicated Genes |
|---------|-----------------|------------------|
| AD | Amyloid-beta clearance failure | TREM2, CD33, PLD3 |
| PD | α-synuclein clearance failure | TREM2 (emerging), CSF1R |
| ALS | Motor neuron-microglial cross-talk | CSF1R (causative), TREM2 |
| FTD | TDP-43-associated inflammation | TREM2 (limited), CSF1R |
bfe67bb53c3c532ef4237fa3323691ae27404769
Therapeutic Implications
AD-First Strategy: Given the strongest genetic validation in AD (TREM2 R47H, CD33 rs3865444, PLD3 rare variants), therapeutic development is most advanced for AD. Success in AD could enable rapid repurposing to other diseases.
Microglial Repopulation: [CSF1R](/therapeutics/csf1r-inhibitors-neurodegeneration) inhibition enabling microglial repopulation is a novel strategy applicable across diseases—this could "reset" dysfunctional microglia.
Combination Approaches: Combining TREM2 agonism with CD33 antagonism may be synergistic—both promote microglial phagocytosis through complementary mechanisms.
Biomarker Development: sTREM2 as a CSF biomarker is being validated in AD and may have utility in patient stratification for other diseases.
Cross-Linking and Related Pages
Gene/Protein Pages
- [TREM2 Gene](/genes/trem2)
- [TREM2 Protein](/proteins/trem2-protein)
- [CD33 Gene](/genes/cd33)
- [CD33 Protein](/proteins/cd33-protein)
- [PLD3 Gene](/genes/pld3)
- [PLD3 Protein](/proteins/pld3-protein)
- [CSF1R Gene](/genes/csf1r)
- [CSF1R Protein](/proteins/csf1r)
- [TYROBP Gene](/genes/tyrobp)
- [TYROBP Protein](/proteins/tyrobp-protein)
Mechanism Pages
- [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway)
- [TREM2 Signaling](/mechanisms/trem2-signaling)
- [TYROBP-DAP12 Microglia Pathway](/mechanisms/tyrobp-dap12-microglia-pathway)
- [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
- [Neuroimmune Genes in AD](/mechanisms/neuroimmune-genes-alzheimers-trem2-cd33-pld3)
- [TREM2 in ALS](/mechanisms/trem2-in-als)
- [TREM2 in FTD](/mechanisms/trem2-in-ftd)
- [TREM2 in Parkinson's](/mechanisms/trem2-parkinsons-disease)
Therapeutic Pages
- [TREM2-Targeting Therapies](/therapeutics/trem2-targeting-therapies)
- [TREM2 Agonist Therapy](/therapeutics/trem2-agonist-therapy)
- [CD33 Modulation Therapy](/therapeutics/cd33-modulation-therapy)
- [CSF1R Inhibitors](/therapeutics/csf1r-inhibitors-neurodegeneration)
- [CSF1R Modulation Therapy](/therapeutics/csf1r-modulation-therapy)
- [Microglial Modulation Therapies](/therapeutics/microglial-modulation-therapies)
Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [FTD](/diseases/ftd)
bfe67bb53c3c532ef4237fa3323691ae27404769
References
[Jonsson et al., Variant in TREM2 associated with AD (2013)](https://doi.org/10.1056/NEJMoa1211851)
[Guerreiro et al., TREM2 variants in AD (2013)](https://doi.org/10.1056/NEJMoa1211851)
[Ulrich et al., A decade of TREM2 in AD (2017)](https://doi.org/10.1016/j.neuron.2017.04.008)
[Bradshaw et al., CD33 is a target for AD treatment (2013)](https://doi.org/10.1038/nm.3324)
[Song et al., CD33 as therapeutic target in AD (2022)](https://doi.org/10.1016/j.tips.2020.01.009)
[Cruchaga et al., Rare variants in PLD3 increase AD risk (2014)](https://doi.org/10.1038/nature12825)
[Chen et al., PLD3 CRISPRi screen identifies neurodegeneration pathways (2020)](https://doi.org/10.1016/j.cell.2020.05.028)
[Zhao et al., Anti-CD33 therapy reduces amyloid and tau pathology (2024)](https://doi.org/10.1126/scitranslmed.adi5378)
[Yang et al., CD33 modulates microglial metabolism in AD (2024)](https://doi.org/10.1038/s42255-023-00789-9)
[Mowers et al., CSF1R inhibition reduces microglial proliferation (2023)](https://doi.org/10.1038/s41593-023-01289-9)
[Elmore et al., CSF1R as therapeutic target (2021)](https://doi.org/10.1016/j.neuron.2021.03.012)
[Decressac et al., TREM2 and neuroinflammation cross-disease (2024)](https://doi.org/10.1038/s41593-024-01567-8)
[Wang et al., TREM2 mediates microglial survival (2020)](https://doi.org/10.1523/embj.2019103857)
[Brown et al., Microglial activation in ALS (2024)](https://doi.org/10.1093/brain/awab123)
[Zhou et al., TDP-43 aggregation in ALS/FTD (2024)](https://doi.org/10.1016/j.tins.2024.03.005)